Skip directly to site content Skip directly to search


Español  Other Languages


An official website of the United States government Here's how you know
 Official icon**Official websites use .gov**
				A .gov website belongs to an official government organization in the United States. Lock icon**Secure .gov websites use HTTPS**
				A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
	CDC LogoCDC Logo
 Search

		×
			NIOSH
			NIOSH

				All CDC
				Submit


The National Institute for Occupational Safety and Health (NIOSH)





Current Intelligence Bulletin 1: Chloroprene						Print
																Related Pages
										January 20, 1975
DHHS (NIOSH) Publication Number 78-127

Introduction
In a letter to Mr. Edward J. Baier, Acting Director, NIOSH, dated December 16, 1974, Dr. John A. Zapp, Director, Haskell Laboratory, E.I. du Pont de Nemours and Company (Du Pont), Wilmington, Delaware, expressed concern over the potential carcinogenicity of chloroprene (2-chlorobutadiene). Du Pont had begun looking closely at this substance recently because of the similarity in chemical structure with vinyl chloride. Du Pont has utilized chloroprene in the production of neoprene (polychloroprene) since 1931.
In the course of a literature search on chloroprene toxicity, Du Pont uncovered two recent Russian articles that suggest an increased incidence of skin and lung cancer in workers exposed to chloroprene. Also, two other articles in the Russian literature were located that described animal experiments in which chloroprene adversely affected embryo development in rats and mice.
Du Pont has informed its employees of the Russian reports and has alerted its customers to the possibility of “escaping chloroprene” during the processing of neoprene. The company is conducting epidemiological studies in humans and animals to ascertain the carcinogenic potential of chloroprene.

Background Information
Chloroprene is a colorless liquid that is slightly soluble in water. It is soluble in alcohol and diethyl ether, and has a vapor density of 3.0, three times that of air, with a boiling point of 59.4°C. Chloroprene is used as a chemical intermediate largely as a monomer for the manufacture of a synthetic rubber.1 It is a chlorine-substituted derivative of 1,3-butadiene. Chloroprene can polymerize spontaneously at room temperature, the process being catalyzed by light, peroxides and other free radical initiators. It can also react with oxygen to form polymeric peroxides. Because of its instability, flammability, and toxicity, chloroprene has no end product uses. It is produced in large quantities mainly for polymerization and marketing under the trade name of Neoprene.2
Neoprene was developed in the U.S. by Carothers3 and was originally introduced by Du Pont in 1931 under the brand name Duprene.4 Although during recent years other suppliers have come on the market with their own brand name, neoprene is generally used as a generic name for polychloroprene rubbers.
Neoprene is obtained by emulsion polymerization of chloroprene (2-chlorobutadiene) and consists mainly of 1,4-transpolychloroprene. There are two main classes, the sulfur modified type and the nonsulfur modified type, indicating the differences in polymerization techniques. Several subtypes of both are available, differing in viscosity and crystallization rate.4
Neoprene’s most valuable properties are its resistance to weathering and oil. It is also resistant to abrasion, heat, flame, oxygen, ozone, and solvents. The main applications of neoprene are in high performance articles such as cable sheaths, hoses, fabrics, adhesives, and a large number of technical rubber articles. The automotive industry is the largest consumer of neoprene.

Toxicity

Human
The primary responses to chloroprene appear to be central nervous system depression and significant injury to lungs, liver, and kidneys.1 Humans exposed to chloroprene have been reported to develop dermatitis, conjunctivitis, corneal necrosis, anemia, temporary loss of hair, nervousness, and irritability. 6
Two Russian reports suggest that chloroprene exposure is associated with an increased incidence of skin and lung cancer.7,8 These studies concern a large-scale epidemiological investigation of industrial workers in the Yerevan region of Russia. During the period 1956-1970, 137 cases of skin cancer were discovered through examination of 24,989 persons over age 25. The population was subdivided into five subgroups according to the character of their employment:
Group I: Persons who never worked in industrial plants
Group II: Persons working in nonchemical industries
Group III: Persons with extended work experience in chloroprene production
Group IV: Persons working in industries using chloroprene derivatives
Group V: Persons working with chemicals unrelated to chloroprene
The following table depicts the results of the study:
The following table depicts the results of the study:
Exposure GroupI
II
III
IV
VNumber examined
8520
8755
684
2250
4780Number of cases
11
35
21
38
32Percent
0.l2
0.40
3.00
1.60
0.66Average age of cases
72.1
68.9
59.6
59.l
64.4Average duration of employment
cases (in years)
16.3
l5.4
9.5
8.7
13.8As can be seen from the table, the incidence of skin cancer was greatest in the chloroprene exposed group, and was substantially greater than that for the three unexposed groups. Persons exposed only to chloroprene derivatives also showed an increased incidence of skin cancer. A gradient in the skin cancer incidence is seen among the five groups reflecting the potential for exposure to toxic chemicals in the work environment. The average age of the cases in both the chloroprene and chloroprene derivative groups was significantly less than that for the other groups. The average duration of employment was much shorter for the chloroprene and chloroprene derivative groups than for the other nonexposed groups. The investigators concluded that development of chloroprene-induced skin cancer is preceded by chronic dystrophic and inflammatory skin ailments which are caused by the binding of chloroprene to the free SH groups in the cells, with the formation of RS-CH compound types.
The incidence of lung cancer among 19,979 workers in the same region was also studied. During the period 1956-1970, 87 cases of lung cancer were identified from the records of the local oncology department. The population was subdivided into four subgroups according to type of employment:
Group I: Workers who had extended contact with chloroprene and/or its derivatives
Group II: The first “control group” consisting of truck drivers, polishers, cabinet makers, stokers, gasoline station attendants, typesetters, painters, and others
Group III: The second “control group” consisting mainly of electricians, carpenters, joiners, arc welders, tinsmiths, furnace workers, etc.
Group IV: The third “control group”consisting of persons who worked in professional occupations
**The following table summarizes the results of the analysis:**
The following table summarizes the results of the analysis:
Exposure GroupI
II
III
IVNumber at risk
2934
4780
6045
6220Number of cases
34
22
11
4Percent
1.16
0.46
0.18
.064Average age of cases
44.5
54.9
59.3
60.2Average duration of employment
cases (in years)
8.7
10.3
19.9
18.5As can be seen from the table, the group with exposure to chloroprene or its derivatives experienced the highest incidence of lung cancer. A gradient in the lung cancer incidence is seen according to exposure group which reflects (roughly) the potential for exposure to toxic chemicals in the work environment. As with the results for skin cancer, the average age and duration of employment for the cases in the chloroprene exposure group is substantially less than for the nonchloroprene control groups. It is interesting to note that the average age of the lung cancer cases in the chloroprene group (44.5) is significantly less than the average age of the skin cancer cases in the same group (about 59).
The authors note that the magnitude of the lung cancer risk in chloroprene-exposed workers is about the same as for chromate workers in the same district.
Of the 34 cases of lung cancer in workers exposed to chloroprene or its derivatives, 18 were among persons having direct and prolonged exposure to the chloroprene monomer. The remaining 16 cases were persons whose exposure was to chloroprene latexes. If this breakdown is applied to the two chloroprene subgroups shown in the skin cancer table (Groups III & IV), the lung cancer rates would be 2.6 (18 ÷ 684) for the group with exposure to chloroprene monomer and 0.7 (16 ÷ 2,250) for the group exposed to chloroprene latexes. This difference presumably reflects the gradient in total amount of exposure to chloroprene.
Animal
Animal experiments have shown that a concentration of 250 ppm in air is toxic and a concentration of 75 ppm may be toxic with continued exposure. Exposure to vapor first causes irritation of the respiratory tract, followed by depression of respiration and, if exposure is continued, asphyxia. The vapor is a central nervous system depressant. It causes severe degenerative changes in the vital organs, particularly the liver and kidneys. In addition, blood pressure is lowered and lung changes accompany exposure, especially at the higher concentrations.6
Chloroprene has caused hyperplasia of lymph nodes and a decrease in the number of lymphocytes in rats.9 During acute and chronic chloroprene exposure, changes in adrenal gland function have also been noted.10
Even in low concentrations, chloroprene affects male reproductive organs causing degenerative changes resulting in reproduction interferences. Male reproductive organs appear to be more susceptible to the effect of chloroprene than female.11
Chloroprene has an effect on embryogenesis. In rats and mice, it causes an increase in the total embryonal mortality and reduction in the fetal weight of offspring of females exposed during pregnancy.12,13
Permissible Occupational Exposures
The American Conference of Governmental Industrial Hygienists established the threshold limit of chloroprene at 25 ppm (90 mg/m3).14 This level was based on the work of Cookl5 and Von Oettingen,11 and is the current Occupational Safety and Health Administration, Department of Labor standard.
Priority List Status
Chloroprene is listed as number 412 on the NIOSH Priority List for Criteria Development for Toxic Substances and Physical Agents. An estimated 2,500 workers are exposed to chloroprene in the United States. The severity rating for chloroprene is 325 on a scale of 0 to 6,000.
Producers and Suppliers
The following is a list of the major producers and suppliers of chloroprene and neoprene in the U.S.:
Chloroprene
Chloroprene
LocationDupont
Victoria, Texas
Laplace, LouisianaPetro-tex Chemical Corp.
-tex Chemical Subsid.
Houston, TexasNeoprene
Neoprene
LocationDupont
Laplace, Louisiana
Louisville, Kentucky
Montague, Michigan*Petro-tex Chemical Corp.
-tex Chemical Subsid.
Houston, Texas—————-
*Shut Down in 1972[*Source: from 1974 Directory of Chemical Producers, USA, Stanford Research Institute, Menlo Park, California, 1974.*]
Annual production figures for chloroprene are not available. Following are the annual figures for neoprene:
Following are the annual figures for neoprene:
Neoprene ProductionYear
(millions of pounds)1968
3401969
3501970
3251971
3401972
3701973
385References
Patty, F.R.: Industrial Hygiene and Toxicology. Interscience Publishers, New York, Vol. II, pp. 1319-1321, 1963
Van Oss, J.F.: Technology: An Encyclopedic Treatment, Barnes and Noble Books, New York, Vol. IV, pp. 211-212, 1972
Carothers, W.H., Williams, I., Collins, A.M., Kirby, J.E.: Polymers and Their Derivatives. II. A new synthetic rubber: Chloroprene and its polymers. J. Amer. Chem. Soc., Vol. 53: 4203-4225, 1931
Van Oss, J.F.: Technology: An Encyclopedic Treatment, Barnes and Noble Books, New York, Vol. V, pp. 482-483, 1972
Number not used.
Sax, N.I.: Properties of Industrial Materials. Van Nostrand Reinhold Company, 3rd Edition, p. 567, New York, 1968
Khachatryan, E.A.: The role of chloroprene in the process of skin neoplasm formation, Gig. Tr. Prof. Zabol., Vol. 18, pp. 54-55, 1972
Khachatryan, E.A.: occurrence of lung cancer among people working with chloroprene. Problems in Oncology, Vol. 18, p. 85, 1972
Agakhanyan, A.G., Fridenshtein, A.Y., Allverdyan, A.G.: of chloroprene toxicosis. Zh. Eksp. Klin. Med., Vol. 13, pp. 3-7, 1973
Allaverdyan, A.G.: Changes in adrenal glands during acute and chronic chloroprene poisoning. Tr. Klin. Otd. NAUCH., Vol. I, pp. 150-157, 1970
Von Oettingen, W.F., Hueper, W.C., Deichmann-Grubler, W., and Wiley, F.H.: 2-Chloro-Butadiene (Chloroprene): Its toxicity and pathology and the mechanism of its action. J. Ind. Hyg. and Toxicology, Vol. 18: 240-270, 1936
Salnikova, L.S.: Embryotropic effects of volatile substances given off by polychloroprene latices. Toksikologiya Novykh Promyshlennykh Khimicheskikh Veschestv, No. 11, pp. 106-111, 1968
Salnikova, L.S., Fomenko, V.N.: Experimental investigation of the influence of chloroprene on embryogenesis. Gig. Tr. Prof. Zabol., Vol. 8, pp. 23-26, 1973
American Conference of Governmental Industrial Hygienists, Documentation of the Threshold Limit Values for Substances in Workroom Air, 3rd Edition, pp. 54-55, 1971
Cook, W.A.: Maximum allowable concentrations of industrial atmospheric contaminants. Ind. Med., Vol. 14, p. 936, 1945
							
					
							Last Reviewed:  June 6, 2014						Source: 	National Institute for Occupational Safety and Health
					Facebook
        Twitter
        LinkedIn
        Syndicate homeNIOSH Publications & Products
NIOSH-Issued Publications
Search NIOSHTIC-2 Research Database
Docket
Documents for Public Review
Peer Review Agenda
Databases
eNews
Federal Register Noticesplus icon
FRN Archive 2007-2010
FRN Archive 2005-2006
FRN Archive 2001-2004
FRN Archive 1996-2000
Press Releases and Updatesplus icon
Press Release Archives 2010-2013
Press Release Archives 2006-2009
Press Release Archives 2001-2005
Press Release Archives 1998-2000
Press Release Archives 1992-1997
Regulations
Regulatory Agenda
Science Blog
Software
Video Error processing SSI file  Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue